Zeit | Aktuelle Nachrichten | ||
---|---|---|---|
Mi | EC grants orphan designation for Pharvaris' deucrictibant drug | ||
Di | Japan's MHLW authorises Regeneron and Sanofi's Dupixent for COPD | ||
Fr | BridgeBio's Beyonttra gains approval in Japan for ATTR-CM treatment | ||
27.03. | US FDA approves Exelixis' Cabometyx for advanced neuroendocrine tumours | ||
26.03. | US FDA grants orphan drug status to Palatin's obesity treatment PL7737 | ||
25.03. | NeuroNOS secures funding for autism treatment development | ||
24.03. | Duke-NUS and NUS Medicine launch centre for metabolomics research | ||
21.03. | FDA approves Novartis' Fabhalta for C3 glomerulopathy treatment | ||
20.03. | Porton Advanced and Eureka to expedite T-cell therapy development | ||
19.03. | Delpharm plans $140m investment to upgrade Boucherville facility in Canada | ||
18.03. | Health Canada approves Arcutis' roflumilast cream 0.15% for atopic dermatitis | ||
17.03. | FDA grants orphan drug status for Korro Bio's AATD therapy | ||
14.03. | FDA clears PDS Biotechnology's Versamune MUC1 combo for mCRC | ||
13.03. | LGM Pharma to expand manufacturing capabilities with $6m investment | ||
12.03. | Aprea and MD Anderson sign agreement for APR-1051 | ||
11.03. | Vivus' Qsymia gains market approval in UAE for obesity treatment | ||
10.03. | UK MHRA approves Vertex's Alyftrek for cystic fibrosis | ||
07.03. | Relief Therapeutics and Renexxion terminate merger talks | ||
06.03. | CordenPharma announces $1bn investment in peptide development and production | ||
05.03. | FairJourney acquires Charles River's San Francisco site | ||
04.03. | FDA approves Celltrion's biosimilars for various indications | ||
03.03. | EMA's CHMP recommends marketing authorisation for Novartis' Fabhalta | ||
28.02. | FDA grants fast track status for Avobis' AVB-114 | ||
27.02. | China's NMPA approves Fosun's NDA of Tenapanor Hydrochloride tablets | ||
26.02. | Health Canada grants marketing authorisation to Kashiv's Pegfilgrastim |